RANI THERAPEUTICS HOLDINGS INC. - CLASS A COMMON

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

14 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Rani Therapeutics to Participate in Upcoming Investor Conferences

07 Nov 2024 15:05:02 By Nasdaq GlobeNewswire

Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist

17 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

08 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Rani Therapeutics to Participate in September Investor Conferences

03 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

06 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Rani Therapeutics to Participate in August Investor Conferences

29 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

22 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

24 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Rani Therapeutics to Participate in May Investor Conferences

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

06 May 2024 15:05:00 By Nasdaq GlobeNewswire

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

20 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

15 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

05 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

14 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

08 Nov 2023 15:05:02 By Nasdaq GlobeNewswire

Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire